

Sara Bringham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9354885/publications.pdf>

Version: 2024-02-01

133
papers

8,781
citations

94269

37
h-index

42291

92
g-index

133
all docs

133
docs citations

133
times ranked

5367
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients. <i>European Journal of Haematology</i> , 2022, 108, 178-189.	1.1	5
2	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2022, 107, 774-775.	1.7	2
3	Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. <i>Frontiers in Oncology</i> , 2022, 12, 851864.	1.3	9
4	Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. <i>Hematological Oncology</i> , 2022, 40, 704-715.	0.8	6
5	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
6	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	1.7	27
7	Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2021, 137, 1154-1165.	0.6	49
8	Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study Oâ€œ12â€œM1. <i>British Journal of Haematology</i> , 2021, 193, 1105-1109.	1.2	11
9	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 437-443.	0.8	11
10	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. <i>Blood Cancer Journal</i> , 2021, 11, 73.	2.8	7
11	Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction. <i>Cancers</i> , 2021, 13, 1631.	1.7	9
12	Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645678.	1.1	8
13	Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis. <i>Leukemia Research</i> , 2021, 104, 106576.	0.4	19
14	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3027-3036.	0.6	40
15	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	1.1	6
16	Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: <scp>ICARIAâ€œMM</scp> subgroup analysis. <i>American Journal of Hematology</i> , 2021, 96, E423-E427.	2.0	10
17	The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Pharmaceuticals</i> , 2021, 14, 20.	1.7	9
18	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021, , .	1.3	0

#	ARTICLE	IF	CITATIONS
19	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. <i>Blood Cancer Journal</i> , 2021, 11, 197.	2.8	5
20	First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. <i>Haematologica</i> , 2020, 105, 1074-1080.	1.7	16
21	Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. <i>Haematologica</i> , 2020, 105, 1937-1947.	1.7	29
22	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	0.8	56
23	Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma. <i>Blood Advances</i> , 2020, 4, 5449-5459.	2.5	17
24	Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8192.	1.8	14
25	New drugs in early development for treating multiple myeloma: all that glitters is not gold. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 989-1004.	1.9	4
26	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 4832-4841.	3.2	33
27	Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1&2 study. <i>Lancet Haematology</i> , 2020, 7, e395-e407.	2.2	65
28	Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. <i>Haematologica</i> , 2020, 106, 291-294.	1.7	17
29	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	0.6	28
30	Ixazomib vs placebo maintenance for newly diagnosed multiple myeloma (NDMM) patients not undergoing autologous stem cell transplant (ASCT): The phase III TOURMALINE-MM4 trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8527-8527.	0.8	5
31	Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8529-8529.	0.8	5
32	Melflufen: A Peptide-Drug Conjugate for the Treatment of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3120.	1.0	35
33	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	0.6	6
34	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27
35	Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy. <i>Cancers</i> , 2019, 11, 622.	1.7	20
36	Approach to the Older Adult With Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 500-518.	1.8	36

#	ARTICLE	IF	CITATIONS
37	Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. <i>Journal of Internal Medicine</i> , 2019, 286, 63-74.	2.7	42
38	Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. <i>Haematologica</i> , 2019, 104, 1640-1647.	1.7	22
39	Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTD)-trial update?. <i>Haematologica</i> , 2019, 104, 2128-2131.	1.7	3
40	Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1. <i>Blood</i> , 2019, 134, 1839-1839.	0.6	1
41	Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis. <i>Blood</i> , 2019, 134, 1893-1893.	0.6	3
42	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2019, 26, 5968-5981.	1.2	6
43	Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. <i>Leukemia</i> , 2018, 32, 1803-1807.	3.3	39
44	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. <i>Leukemia</i> , 2018, 32, 979-985.	3.3	25
45	Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 209-218.	1.0	18
46	Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft "Allograft in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 189-193.	2.0	21
47	Updated results of a phase 2 study of panobinostat combined with melphalan, thalidomide and prednisone (MPT) in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 1271-1273.	0.6	6
48	Determining treatment intensity in elderly patients with multiple myeloma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 917-930.	1.1	10
49	Cardiovascular adverse events in modern myeloma therapy " Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). <i>Haematologica</i> , 2018, 103, 1422-1432.	1.7	70
50	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	2.0	25
51	Maintenance Treatment and Survival in Patients With Myeloma. <i>JAMA Oncology</i> , 2018, 4, 1389.	3.4	67
52	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 533-540.	0.2	9
53	Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). <i>Leukemia</i> , 2018, 32, 1697-1712.	3.3	83
54	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 155-155.	0.6	21

#	ARTICLE	IF	CITATIONS
55	Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant. <i>Blood</i> , 2018, 132, 595-595.	0.6	22
56	Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study. <i>Blood</i> , 2018, 132, 305-305.	0.6	30
57	MPO250 Combined with Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs. <i>Blood</i> , 2018, 132, 1980-1980.	0.6	1
58	Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2738-2740.	0.6	1
59	New Agents in Multiple Myeloma: An Examination of Safety Profiles. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 391-407.e5.	0.2	41
60	How is patient care for multiple myeloma advancing?. <i>Expert Review of Hematology</i> , 2017, 10, 551-561.	1.0	11
61	Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. <i>European Journal of Haematology</i> , 2017, 98, 289-295.	1.1	2
62	Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. <i>American Journal of Hematology</i> , 2017, 92, 244-250.	2.0	19
63	Systemic virotherapy for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-13.	1.4	11
64	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 3279-3289.	0.8	535
65	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	0.6	7
66	Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2016, 127, 1102-1108.	0.6	78
67	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.2	9
68	A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. <i>Leukemia</i> , 2016, 30, 1320-1326.	3.3	38
69	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. <i>Leukemia and Lymphoma</i> , 2016, 57, 537-556.	0.6	17
70	A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients. <i>Blood</i> , 2016, 128, 1145-1145.	0.6	6
71	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. <i>Blood</i> , 2016, 128, 3469-3469.	0.6	0
72	An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials. <i>Blood</i> , 2016, 128, 3336-3336.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials. <i>Blood</i> , 2016, 128, 995-995.	0.6	0
74	Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. <i>Blood</i> , 2015, 125, 2068-2074.	0.6	586
75	Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie Ematologiche dell'Adulto Multiple Myeloma Working Party study. <i>Stem Cell Research and Therapy</i> , 2015, 6, 64.	2.4	25
76	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	1.7	289
77	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study. <i>Blood</i> , 2015, 126, 1828-1828.	0.6	4
78	Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial. <i>Blood</i> , 2015, 126, 392-392.	0.6	4
79	Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 927-927.	0.6	2
80	Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. <i>Leukemia</i> , 2014, 28, 222-225.	3.3	77
81	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 333-342.	5.1	256
82	Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 1193-1209.	1.9	6
83	Monoclonal antibodies currently in Phase II and III trials for multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1127-1144.	1.4	13
84	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-640.	0.8	198
85	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	3.3	55
86	Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. <i>Blood</i> , 2014, 124, 63-69.	0.6	126
87	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. <i>Haematologica</i> , 2014, 99, 1114-1122.	1.7	42
88	Age and aging in blood disorders: multiple myeloma. <i>Haematologica</i> , 2014, 99, 1133-1137.	1.7	50
89	Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study. <i>Blood</i> , 2014, 124, 175-175.	0.6	4
90	Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study. <i>Blood</i> , 2014, 124, 2110-2110.	0.6	5

#	ARTICLE	IF	CITATIONS
91	The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy. <i>Blood</i> , 2014, 124, 4740-4740.	0.6	0
92	Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1517-1527.	1.5	17
93	Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. <i>Haematologica</i> , 2013, 98, 980-987.	1.7	193
94	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	0.6	8
95	A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 536-536.	0.6	13
96	A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 685-685.	0.6	8
97	A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2013, 122, 687-687.	0.6	15
98	Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8517-8517.	0.8	6
99	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1209-1222.	1.5	9
100	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. <i>Blood</i> , 2012, 119, 933-939.	0.6	260
101	Update on the use of defibrotide. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 353-361.	1.4	21
102	Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 200-200.	0.6	13
103	Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2012, 120, 730-730.	0.6	4
104	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. <i>Blood</i> , 2012, 120, 2921-2921.	0.6	0
105	Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. <i>Leukemia</i> , 2011, 25, 1627-1631.	3.3	51
106	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. <i>Blood</i> , 2011, 118, 1239-1247.	0.6	243
107	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	0.6	309
108	Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients. <i>Blood</i> , 2011, 118, 996-996.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,. Blood, 2011, 118, 3970-3970.	0.6	0
110	Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood, 2010, 115, 1873-1879.	0.6	87
111	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, 116, 4745-4753.	0.6	361
112	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology, 2010, 28, 800-807.	0.8	166
113	Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial. Journal of Clinical Oncology, 2010, 28, 5101-5109.	0.8	400
114	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. Blood, 2010, 116, 525-525.	0.6	2
115	Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities. Blood, 2010, 116, 781-781.	0.6	6
116	Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients.. Blood, 2009, 114, 128-128.	0.6	16
117	Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.. Blood, 2009, 114, 1868-1868.	0.6	2
118	Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients.. Blood, 2009, 114, 3419-3419.	0.6	1
119	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. Blood, 2009, 114, 3887-3887.	0.6	5
120	A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens.. Blood, 2009, 114, 492-492.	0.6	14
121	Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 2008, 22, 414-423.	3.3	787
122	Role of thalidomide in previously untreated patients with multiple myeloma. Expert Review of Anticancer Therapy, 2008, 8, 1569-1580.	1.1	4
123	Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood, 2008, 112, 3107-3114.	0.6	339
124	A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens. Blood, 2008, 112, 3017-3017.	0.6	17
125	Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia. Blood, 2008, 112, 2784-2784.	0.6	1
126	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMAâ€™Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	0.8	301

#	ARTICLE	IF	CITATIONS
127	Melphalan and its role in the management of patients with multiple myeloma. Expert Review of Anticancer Therapy, 2007, 7, 945-957.	1.1	43
128	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood, 2007, 109, 2767-2772.	0.6	174
129	Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet, The, 2006, 367, 825-831.	6.3	775
130	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. Clinical Lymphoma and Myeloma, 2006, 6, 475-477.	1.4	22
131	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. European Journal of Haematology, 2006, 76, 273-277.	1.1	51
132	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). Leukemia, 2004, 18, 133-138.	3.3	30
133	Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood, 2004, 104, 3052-3057.	0.6	305